<DOC>
	<DOC>NCT01118325</DOC>
	<brief_summary>The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.</brief_summary>
	<brief_title>An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Any Percutaneous Coronary Intervention, more than 3 months prior to randomization Previous documented acute coronary syndrome (ACS), more than 3 months prior to randomisation Treatment with ASA ACS, transient ischemic attack (TIA), or Stroke within the 3 months prior to randomisation Known concurrent disease of stroke or TIA with atrial fibrillation Persons who are being treated with blood clotting agents that cannot be stopped</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Stable Coronary Artery Disease</keyword>
	<keyword>Platelet Aggregation</keyword>
</DOC>